Couverture de Detecting Chronic Fatigue Epigenetic Biomarkers & Breakthrough Blood Testing

Detecting Chronic Fatigue Epigenetic Biomarkers & Breakthrough Blood Testing

Detecting Chronic Fatigue Epigenetic Biomarkers & Breakthrough Blood Testing

Écouter gratuitement

Voir les détails
Could a blood test finally provide answers for millions living with chronic fatigue syndrome (CFS/ME)? In this episode, Alexandre Akoulitchev and Dmitry Pshezhetskiy reveal a groundbreaking approach using epigenetic biomarkers to detect biological signatures associated with this complex, hard-to-diagnose condition. Their work leverages cutting-edge molecular medicine and translational research to provide earlier, more objective detection of CFS/ME—offering hope for patients who have long struggled with uncertainty and delayed diagnoses. In this conversation, we explore: · How a blood-based biomarker test may identify chronic fatigue syndrome more reliably. · The role of epigenetics in understanding invisible, multi-system illnesses. · The four core symptoms of CFS/ME and why conventional diagnostics often fail. · How inflammation and immune signals contribute to fatigue and disease progression. Alexandre Akoulitchev, cofounder of Oxford BioDynamics and creator of the EpiSwitch biomarker platform, and Dmitry Pshezhetskiy, Professorial Research Fellow at Norwich Medical School, bring decades of expertise in molecular biology, genome regulation, and translational research to this discussion. Learn more about Alexandre Akoulitchev here and Dmitry Pshezhetskiy here. Episode also available on Apple Podcasts: https://apple.co/38oMlMr 🛍️ Recommended Products & Reads from This Episode: 🎙️ Blue Yeti USB Microphone – A top choice for aspiring podcasters and speakers who want professional-grade audio at home. 👉Check it out Note: These are affiliate links. If you make a purchase through them, we may earn a small commission at no extra cost to you. It helps support the podcast. Thank you!
adbl_web_anon_alc_button_suppression_t1
Aucun commentaire pour le moment